Of these publications, 69 articles were excluded because 13 of them provided deficient or inaccessible information and the rest were excluded because they compared HER2-targeted agents for HER2-negative or triple-negative breast cancer, and 19 articles were excluded because they focused on single drug comparison without combination with standard chemotherapy or concentrated on different administration order or approach. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.